Detection of matalloproteinase-2-8-9 and tissue protease inhibitor serum levels in preterm babies with respiratory distress syndrome

Abstract

Introduction and purpose: Metalloproteinases (MMP) have an increasing attention in the pathogenesis of respiratory distress syndrome (RDS) that is frequently seen in preterm babies. MMPs are included in the structure and function of extracellular matrix and basal membrane and in the destruction of some structural elements. They are inhibited by specific tissue metalloproteinase inhibitor (TIMPs). In previous studies, changes in MMP 2-8-9 and TIMP-2 levels were reported. We aimed to detect MMP 2-8-9 and TIMP-2 levels in serum samples of preterm babies with RDS. Material and methods: Study group was formed by 24 RDS patients under 37 weeks of gestational age according to the new Ballard scale. Twenty-one baby without respiratory distress and any additional problem was established as control group. MMP-2, MMP-8, MMP-9 and TIMP-2 levels were studied in 2 cc blood samples which were collected in the first 48 hours of delivery of all included babies. Results: No significant difference was found between the levels of MMP 2-8-9 and TIMP-2 in study and control groups.Conclusion: Further studies are needed to suggest that there is no difference of MMP and TIMP levels in mild-moderate grade RDS patients.

Keywords

• respiratory distress syndrome, metalloproteinases

Respiratuar Distres Sendromlu Pretermlerde Serumda Metalloproteinaz-2-8-9, ve Doku Proteaz İnhibitör-2 Düzeylerinin Belirlenmesi

Abstract

Giriş ve Amaç: Son yıllarda preterm bebeklerde sıklıkla izlenen respiratuar distres sendromu'nun (RDS) patogenezinde metalloproteinazların rolü üzerinde durulmaktadır. Metalloproteinazlar (MMP); ekstrasellüler matriks ve bazal membranın yapısal ve fonk-siyonel işlevlerinde rol oynayarak bazı yapısal elemanların yıkımında görev alarak spesifik doku metalloproteinaz inhibitörü (TIMPs) tarafından inhibe edilirler. Önceki çalışmalarda RDS'li preterm hastaların BAL sıvılarında MMP 2-8-9 ve TIMP-2'nin düzeylerindeki değişiklikler gösterilmiştir. Bu çalışmadaki amacımız RDS'li preterm hastalardaki serum örneklerinde MMP 2-8-9 ve TIMP-2 düzeylerini belirlemektir. Gereç ve Yöntem: Gestasyon yaşları yeni ballard skalasına göre 37 haftanın al-tında RDS tanısı alan 24 hasta çalışma grubunu, solunum sıkıntısı gelişmeyen ve ek so-runu olmayan 21 hasta ise kontrol grubunu oluşturdu. Çalışmaya alınan tüm bebeklerden ilk 48 saat içerisinde 2cc venöz kan örneği alınarak MMP-2, MMP-8, MMP-9 ve TIMP-2 düzeyleri çalışıldı. Çalışma ve kontrol grubunda serum MMP 2-8-9 ve TIMP-2 düzeyleri arasında istatistiksel olarak anlamlı fark bulunmadı. Sonuç: Hafif-orta düzey RDS'li hastalarda MMP ve TIMP düzeylerinde değişik-lik olmadığını söyleyebilmek için başka çalışmalara ihtiyaç vardır.

Keywords

• Respiratuar distres sendromu, Metalloproteinazlar

References

1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999 30;274(31):21491-21494.
2. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: W.C. Parks and R.P. Mecham, Editors, Matrix Metalloproteinases, Academic Press, San Diego, CA (1998), pp299–356
3. Cederqvist K, Sorsa T, Tervahartiala T, Maisi P, Reunanen K, Lassus P, Andersson S. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics. 2001;108(3):686-92
4. Schulz CG, Sawicki G, Lemke RP, Roeten BM, Schulz R, Cheung PY. MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates. Pediatr Res 2004;55(5):794-801
5. Fukunaga S, Ichiyama T, Maeba S, Okuda M, Nakata M, Sugino N, Furukawa S. MMP-9 and TIMP-1 in the cord blood of premature infants developing BPD. Pediatr Pulmonol. 2009 Mar;44(3):267- 72.
6. Davies PL, Spiller OB, Beeton ML, Maxwell NC, Remold- O'Donnell E, Kotecha S. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax. 2010 Mar;65(3):246-51.
7. Bry K, Hogmalm A, Bäckström E. Mechanisms of inflammatory lung injury in the neonate: lessons from a transgenic mouse model of bronchopulmonary dysplasia. Semin Perinatol. 2010 Jun;34(3):211-21.
8. Hergrueter AH, Nguyen K, Owen CA. Matrix metalloproteinases: all the RAGE in the acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2011 Apr;300(4):L512-5.

9. Corbel M, Boichot E, Lagente V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz J Med Biol Res. 2000; 33 (7): 749-754
10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827-39.
11. Trocmé C, Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem. 1998;273(32):20677-84
12. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008 ;29(5):290-308
13. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997 Oct;74(2):111-22.
14. Sweet DG, Curley AE, Chesshyre E, Pizzotti J, Wilbourn MS, Halliday HL, Warner JA. The role of matrix metalloproteinases -9 and -2 in development of neonatal chronic lung disease. Acta Paediatr. 2004;93(6):791-796
15. Sweet DG, Wilbourn MS, Warner JA, Howarth P, Halliday HL. Matrix metalloproteinases in bronchoalveolar lavage fluid from preterm infants at high risk of developing bronchopulmonary dysplasia. Biol Neonat 1998;74:43–56
16. Ekekezie II, Thibeault DW, Simon SD, Norberg M, Merrill JD, Ballard RA, Ballard PL, Truog WE. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/
17. tissue inhibitor of metalloproteinase-1 ratio are present in tracheal
18. aspirate fluids of infants who develop chronic lung disease.
19. Pediatrics. 2004;113(6):1709-1714.